xBiotech USA, Inc.

115 articles about xBiotech USA, Inc.

• 2 Fallen Biotech Stocks Worth Chasing

  7/8/2016

• XBiotech's Colorectal Cancer Drug Claims Fall Apart, Shares Plummet

  7/6/2016

• Xbiotech To Present Positive Preliminary Survival Data On Xilonix At The 18th European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer

  5/24/2016

• XBiotech Provides First Quarter 2016 Corporate And Clinical Update

  5/18/2016

• XBiotech Names Industry Veteran Dawn McCollough To Head Clinical Operations

  5/16/2016

• XBiotech USA To Provide First Quarter 2016 Business Update On May 18

  5/11/2016

• XBiotech USA Appoints Amgen Veteran Scott Whitehurst As Chief Financial Officer

  5/3/2016

• XBiotech USA To Present Pivotal Phase III Data On Xilonix At European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer

  4/19/2016

• European Medicines Agency Grants Accelerated Assessment Of Marketing Authorization Application For Xilonix, XBiotech USAh’s True Human Therapeutic Antibody Treatment For Advanced Colorectal Cancer

  4/4/2016

• Xbiotech To Deliver Presentation On Novel Study Design And Phase III Results From European Study On Xilonix During Meeting At The European Parliament

  3/2/2016

• XBiotech USA Engages In Research For Heart Attack Antibody Therapy

  2/19/2016

• Xbiotech Announces Agreement With The NCIC Clinical Trials Group To Collaborate On Phase II Study In Non-Small Cell Lung Cancer (NSCLC)

  12/11/2015

• Xbiotech Announces Positive Results In European Phase III Study For Its Breakthrough Therapy For Colorectal Cancer

  12/7/2015

• Xbiotech Added To The MSCI US Small Cap 1750 And The MSCI Investable Market 2500 Indexes

  11/20/2015

• XBiotech Provides Third Quarter 2015 Corporate And Clinical Update

  11/12/2015

• Xbiotech Identifies Positive Donors For Anti-Clostridium Difficile Therapeutic Antibody Only Two Weeks After Initial Screening

  11/11/2015

• Xbiotech Announces Positive Results For Its Anti-Ebola Therapeutic Candidates Following Evaluation By USAMRIID

  11/9/2015

• XBiotech To Provide Third Quarter Business Update

  11/5/2015

• XBiotech Initiates Program To Develop Antibody Against Clostridium Difficile

  10/26/2015

• XBiotech Strengthens Intellectual Property Portfolio For Its True Human Antibody Technology

  10/19/2015